Aegerion Pharmaceuticals (AEGR) gains 4.5% after Deutsche Bank initiates coverage with a Buy...

|About: Aegerion Pharmaceuticals (AEGR)|By:, SA News Editor

Aegerion Pharmaceuticals (AEGR) gains 4.5% after Deutsche Bank initiates coverage with a Buy rating and $19 price target. An analyst with the firm says the biotech firm is undervalued with the full potential of its drug pipeline and upcoming FDA approvals not yet factored into its share price.